electroCore vs Electromed
ECOR and ELMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ECOR and ELMD compare
Electromed is the larger company, worth 4.3 times as much as electroCore ($203M against $47.3M).
electroCore grew revenue faster over the last twelve months (27.3% versus 14.1% for Electromed).
Electromed keeps more of each dollar of sales as profit, with a net margin of 15.8% compared with −33.5% at electroCore.
Electromed scores higher on the StockData Score (21 against 7 for electroCore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ECOR | ELMD |
|---|---|---|
| Size and price | ||
| Market cap | $47.3M | $203M |
| Share price | $5.25 | $24.32 |
| Change, 1 year | −13.4% | −4.2% |
| Change, 5 years | −53.8% | 106% |
| Beta (5Y) | 1.09 | 0.49 |
| Employees | 83 | 197 |
| StockData Score | ||
| Total score | 7 | 21 (better) |
| Valuation score | 1 | 5 (better) |
| Growth score | 4 | 5 (better) |
| Performance score | 1 | 5 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 17.6× |
| P/S | 1.2× (better) | 2.7× |
| P/B | – | 3.9× |
| EV/EBITDA | – | 12.8× |
| P/FCF | – | 23.4× |
| PEG | – | 0.33 |
| FCF yield | −23.0% | 4.3% (better) |
| Fair value | – | $33.69 |
| Margin of safety | – | 27.8% |
| Growth | ||
| Revenue growth (TTM) | 27.3% (better) | 14.1% |
| Revenue growth, 5Y average | 55.7% (better) | 15.6% |
| Net income growth (TTM) | – | 45.5% |
| EPS growth (TTM) | – | 48.4% |
| EPS growth, 5Y average | – | 36.9% |
| Profitability | ||
| Gross margin | 87.7% (better) | 79.0% |
| Operating margin | −33.1% | 19.5% (better) |
| Net margin | −33.5% | 15.8% (better) |
| FCF margin | −28.7% | 11.5% (better) |
| Return on equity | – | 24.5% |
| Return on invested capital | – | 34.3% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −960.7× | – |
| Current ratio | 1.34 | 7.19 (better) |
| Altman Z-score | −14.80 | 17.69 (better) |
| Piotroski F-score | 3 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 3.6% |
| Shareholder yield | 0.00% | 3.6% (better) |
| Ownership | ||
| Held by institutions | 11.4% | 55.6% |
| Held by insiders | 16.6% | 11.4% |
| Insider net buying, 12 months | −$721K (better) | −$2.2M |
| Short interest, % of float | 4.8% | 2.4% |
Go deeper
- ECOR stock overview
- ECOR income statement
- ECOR valuation and score
- ELMD stock overview
- ELMD income statement
- ELMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.